KATE BROWNE: Open Payments
NPI 1942956735 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$597 in 25 payments from 10 companies in 2025. Trend: 2023 $305 · 2024 $400 · 2025 $597
Food & beverage: $504Education: $93
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 11 | $210 |
| Incyte Corporation | 1 | $93 |
| AstraZeneca Pharmaceuticals LP | 3 | $68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $50 |
| Celgene Corporation | 2 | $48 |
| Adaptive Biotechnologies Corporation | 2 | $34 |
| E.R. Squibb & Sons, L.L.C. | 1 | $29 |
| ABBVIE INC. | 1 | $29 |
| Immunocore Limited | 1 | $20 |
| BeiGene USA, Inc. | 1 | $18 |
Products named: KISQALI, REBLOZYL, IMFINZI, SCEMBLIX, clonoSEQ, EPKINLY, PLUVICTO, LUTATHERA.
Industry payments across IL — which companies pay providers there.
